Invasive Breast Cancer
HR+/HER2-, HER2-Positive, and Triple-Negative (TNBC) subtypes. Covers CDK4/6 inhibitors (Ribociclib, Abemaciclib), T-DXd (Enhertu), AC-T regimens, and BRCA1/2 PARP inhibitors.
Read Full Clinical Guide →Empathetic, peer-reviewed cancer education synthesizing NCCN, ASCO, ESMO, and MASCC clinical guidelines with direct navigation to 140+ verified financial assistance grants and organ comorbidity management.
HR+/HER2-, HER2-Positive, and Triple-Negative (TNBC) subtypes. Covers CDK4/6 inhibitors (Ribociclib, Abemaciclib), T-DXd (Enhertu), AC-T regimens, and BRCA1/2 PARP inhibitors.
Read Full Clinical Guide →Adenocarcinoma and Squamous cell carcinoma. Actionable driver mutations (EGFR, ALK, ROS1, KRAS G12C, BRAF, MET), Osimertinib, and Pembrolizumab immunotherapy.
Read Full Clinical Guide →Staging I through IV. Microsatellite instability (MSI-H/dMMR), RAS/BRAF mutations, FOLFOX/FOLFIRI chemotherapy, and anti-EGFR vs anti-VEGF biologic selection.
Read Full Clinical Guide →NCCN Resectability criteria (Resectable, Borderline, Metastatic), CA 19-9 monitoring, mFOLFIRINOX vs Gem/nab-Paclitaxel, and Olaparib maintenance for germline BRCA/PALB2.
Read Full Clinical Guide →ISUP Gleason Grade Groups 1–5, PSA kinetics, castration-sensitive vs castration-resistant (mCRPC), ARPIs (Enzalutamide, Abiraterone), and Pluvicto PSMA radioligand.
Read Full Clinical Guide →Twelve dedicated open-access portals addressing cancer comorbidities, supportive care, and patient aid: